Abstract
Recent research has raised hopes for impressively accurate screening for cancer with molecular biomarkers. These molecular markers will probably be more sensitive and specific than older screening modalities, as well as easier to use. In this Essay, I argue that these sensitive screening tests might be clinically valuable — but that they will present unique issues in implementation and interpretation. These issues are likely to affect the way clinicians conduct screening and the way that they make diagnoses in individuals who screen positive for cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel Graphene Biosensor Based on the Functionalization of Multifunctional Nano-bovine Serum Albumin for the Highly Sensitive Detection of Cancer Biomarkers
Nano-Micro Letters Open Access 09 March 2019
-
Genetic variations of MUC17 are associated with endometriosis development and related infertility
BMC Medical Genetics Open Access 19 August 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295–2303 (2011).
Duffy, M. J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem. 47, 624–630 (2001).
Kulasingam, V., Pavlou, M. P. & Diamandis, E. P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nature Rev. Cancer 10, 371–378 (2010).
Gigerenzer, G., Mata, J. & Frank, R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J. Natl Cancer Inst. 101, 1216–1220 (2009).
Schwartz, L. M., Woloshin, S., Fowler, F. J. Jr & Welch, H. G. Enthusiasm for cancer screening in the United States. JAMA 291, 71–78 (2004).
Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002).
Visintin, I. et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14, 1065–1072 (2008).
Ransohoff, D. F. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97, 315–319 (2005).
Zhu, C. S. et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev. Res. 4, 375–383 (2011).
Division of Cancer Prevention, US National Cancer Institute. The early detection research network, fifth report. NIH Publication 10–7696 (2011).
Croswell, J. M., Baker, S. G., Marcus, P. M., Clapp, J. D. & Kramer, B. S. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann. Intern. Med. 152, 505–512 (2010).
Villanueva, J. et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271–284 (2006).
Pang, W. W., Abdul-Rahman, P. S., Wan-Ibrahim, W. I. & Hashim, O. H. Can the acute-phase reactant proteins be used as cancer biomarkers? Int. J. Biol. Markers 25, 1–11 (2010).
Grubb, R. L. et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol. Biomarkers Prev. 18, 748–751 (2009).
Rundle, A., Richards, C. & Neugut, A. I. Hemodilution of prostate-specific antigen levels among obese men. Cancer Epidemiol. Biomarkers Prev. 18, 2343–2344 (2009).
Loeb, S., Gashti, S. N. & Catalona, W. J. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol. Oncol. 27, 64–66 (2009).
Lu, H., Ouyang, W. & Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res. 4, 221–233 (2006).
Hussain, S. P. & Harris, C. C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121, 2373–2380 (2007).
Cole, P. & Morrison, A. S. Basic issues in population screening for cancer. J. Natl Cancer Inst. 64, 1263–1272 (1980).
Dorigo, O. & Berek, J. S. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev. Res. 4, 1356–1359 (2011).
Black, W. C. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. J. Natl Cancer Inst. 92, 1280–1282 (2000).
Pollak, M. N. & Foulkes, W. D. Challenges to cancer control by screening. Nature Rev. Cancer 3, 297–303 (2003).
Folkman, J. & Kalluri, R. Cancer without disease. Nature 427, 787 (2004).
Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).
Esserman, L. Shieh, Y. & Thompson, I. Rethinking screening for breast cancer and prostate cancer. JAMA 302, 1685–1692 (2009).
Kovacs, G. L. et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 15, 152–157 (2005).
Welch, H. G. & Black, W. C. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127, 1023–1028 (1997).
Nielsen, M. Autopsy studies of the occurrence of cancerous, atypical and benign epithelial lesions in the female breast. APMIS Suppl. 10, 1–56 (1989).
Biesheuvel, C., Barratt, A., Howard, K., Houssami, N. & Irwig, L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 8, 1129–1138 (2007).
Troyer, D. A. et al. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol. Biomarkers Prev. 18, 2717–2722 (2009).
Jaffer, F. A. & Weissleder, R. Molecular imaging in the clinical arena. JAMA 293, 855–862 (2005).
Kwon, R. S., Sahani, D. V. & Brugge, W. R. Gastrointestinal cancer imaging: deeper than the eye can see. Gastroenterology 128, 1538–1553 (2005).
Wang, T. D. & Van Dam, J. Optical biopsy: a new frontier in endoscopic detection and diagnosis. Clin. Gastroenterol. Hepatol. 2, 744–753 (2004).
Marten, K. et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122, 406–414 (2002).
Fletcher, R. H. Carcinoembryonic antigen. Ann. Intern. Med. 104, 66–73 (1986).
Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371–375 (2002).
Kawakami, K. et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92, 1805–1811 (2000).
Sorenson, G. D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 6, 2129–2137 (2000).
Nagasaka, T. et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl. Cancer Inst. 101, 1244–1258 (2009).
O'Shaughnessy, J. A. et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8, 314–346 (2002).
Cooper, K. et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 14, 1–206 (2010).
Cuzick, J. et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 12, 496–503 (2011).
Hruban, R. H., van der Riet, P., Erozan, Y. S. & Sidransky, D. Brief report: molecular biology and the early detection of carcinoma of the bladder-the case of Hubert H. Humphrey. N. Engl. J. Med. 330, 1276–1278 (1994).
Acknowledgements
Supported by U01 CA086400. Thanks are due to D. Brenner and S. Syngal for helpful comments.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Baron, J. Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer 12, 368–371 (2012). https://doi.org/10.1038/nrc3260
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3260
This article is cited by
-
Novel Graphene Biosensor Based on the Functionalization of Multifunctional Nano-bovine Serum Albumin for the Highly Sensitive Detection of Cancer Biomarkers
Nano-Micro Letters (2019)
-
Genetic variations of MUC17 are associated with endometriosis development and related infertility
BMC Medical Genetics (2015)